@HealthVitalsNews11dNovo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pillNovo Nordisk and Eli Lilly's stocks dropped significantly after Hims & Hers announced it would offer a copy of the Wegovy weight-loss pill for $49, much less than Novo Nordisk's $149 branded version. Novo's shares fell 7% and Eli Lilly's dropped 6.1% on the news, while Hims & Hers' stock surged 10%. Novo launched Wegovy in the U.S. in early January, with 170,000 people already using the medication. Hims & Hers claims its copy is legal as it uses a different formulation and delivery system than the FDA-approved version.
@HealthVitalsNews27dIndia faces second-highest economic burden due to diabetes; doctor explains the growing crisis, prediabetes and shares prevention tips | - The Times of IndiaDiabetes has become one of the biggest economic burdens of India, a study has found. As per the new international studyby researchers from the International Institute for Applied Systems Analysis and the Vienna University of Economics and Business in Austria found that India face
@HealthVitalsNews
